Death Every 10 Seconds Spurs Big Pharma’s Lung Drug Race: Health
This article is for subscribers only.
There’s a new competition brewing in the $10 billion market for drugs to treat deadly lung diseases as the growing number of smokers in emerging markets drives demand.
Novartis AG aims to convince doctors that its new Ultibro medicine for chronic obstructive pulmonary disease is better than GlaxoSmithKline Plc’s blockbuster Advair, which is also used to treat asthma. Glaxo, meanwhile, has developed new products in anticipation of the day that Advair faces competition from generic copies.